quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:01:00·196d
PRRelease
Editas Medicine Inc. logo

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

EDIT· Editas Medicine Inc.
Health Care
Original source

Companies

  • EDIT
    Editas Medicine Inc.
    Health Care

Recent analyst ratings

  • Apr 28UpdateH.C. Wainwright$3.00
  • Dec 16UpdateAnalyst-
  • Dec 13UpdateChardan Capital Markets-
  • Dec 13UpdateTruist-
  • Dec 13UpdateStifel$3.00
  • Dec 11UpdateWells Fargo$4.00

Related

  • SEC16d
    Editas Medicine Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
  • SEC28d
    Editas Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR28d
    Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Editas Medicine Inc.
  • INSIDER38d
    SEC Form 4 filed by CEO O'Neill Gilmore Neil
  • INSIDER38d
    SEC Form 4 filed by SVP, Chief Financial Officer Parison Amy
  • INSIDER38d
    SEC Form 4 filed by EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda
  • SEC45d
    SEC Form 10-K filed by Editas Medicine Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022